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1. Introduction 
ALL is a malignant disorder of the blood system characterized by uncontrolled proliferation 
of bone marrow-derived B- and T-lymphocyte progenitors that are arrested in an early stage 
of development (Pui et al, 2008). This arrest is caused by aberrant gene fusions or 
inappropriate expression of oncogenes. The lymphoblasts replace the normal marrow 
elements, resulting in a substantial decrease in the production of normal blood cells. 
Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. 
Moreover, the expanding lymphoblasts can escape the bone marrow niche, and manifest as 
heptospenomegaly, enlargement of lymph nodes, thymus, and gonads, and infiltration of 
the meninges (Pui et al, 2008). 
ALL has a peak incidence between the ages of 2 to 5 years, representing 25% of the 
malignant disorders in childhood (Pui et al, 2006). Currently, ALL is treated by 
administration of cyclic induction chemotherapy, which is intended to kill the majority of 
leukemic cells, followed by a consolidation chemotherapy, which should destroy any 
remaining leukemic cells (Freycon et al, 2008; Pui et al, 2008). For high risk patients, 
myeloablative regimens followed by allogeneic hematopoietic stem-cell transplantation are 
indicated to achieve more extensive eradication of leukemia and to induce graft versus 
leukemia effects against the disease. The implementation of risk-adapted strategies, which 
tailor the intensity of therapy to the risk of relapse, has resulted in a cure rate of more than 
80% in children being long-term survivors (Pui et al, 2006). In contrast to the successes 
obtained with paediatric patients, treatment outcomes for adult patients remain poor with 
less than 40% being long-term survivors (Vitale et al, 2006). Due to relative nonspecific 
action and narrow therapeutic indices of antileukemic medications, serious short and long-
term complications arise as a result of the intensification of many current therapies (Barr et 
al, 2008). 
The identification of genetic and epigenetic changes that are associated with 
leukemogenesis and altered drug response provides insights into the molecular basis of 
ALL. The translation to the clinic might serve as a model for optimizing the treatment and 
generate innovative therapeutic agents. Finally, these could be implemented in more 
effective, and potentially less toxic, individually tailored treatment protocols, based on the 
underlying molecular abnormalities of a patient’s leukemia. This review will concentrate 
on novel agents that show promising anti-leukemic activity in pre-clinical studies or 
clinical trials. 
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2. CXCR4 inhibitors 
Several studies have been reported on the involvement of chemokines and adhesion molecules 
in the process of mobilization of ALL cells. Among the most studied molecules are the 
chemokine receptor CXCR4 and the chemokine stromal cell-derived factor-1 (SDF-1, CXCL12); 
in particular CXCR4, was found to be highly expressed in bone-marrow derived ALL cells 
enabling these cells to migrate across a gradient of CXCL12 concentrations (Crazzolara et al, 
2001). Elevated levels of CXCL12 are not only found in the bone marrow environment, but also 
at extramedullary sites associated with ALL induced organ infiltration (Muller et al, 2001). 
Subsequently CXCL12 can act as survival and proliferation factor for CXCR4 positive cells and 
protect them from spontaneous and chemotherapy-induced apoptosis (Burger et al, 2000). In 
several studies, CXCL12 is also reported in the process of homing of CXCR4 positive cells in 
NOD/SCID xenograft mouse models (Nagasawa et al, 1996). Of note is the direct correlation 
between high CXCR4 expression on lymphoblasts and the extent of extramedullary infiltration 
in patients with ALL (Crazzolara et al, 2001). 
Direct evidence for the involvement of CXCR4 and CXCL12 in the release of ALL cells in the 
blood is demonstrated from the finding that treatment of mice with small compounds that 
target CXCR4 and its ligand can disrupt the interaction between ALL cells and the stromal 
microenvironment. The polyphemusin II-derived inhibitors T140, TC140012, T134, and the 
bicyclam AMD3100 effectively inhibit CXCR4, and CXCL12-driven migration into bone 
marrow layers in vitro, thus enhancing the cytotoxic and anti-proliferative effects of the 
currently used agents vincristine and dexamethasone (Juarez et al, 2003). Disruption of the 
interaction of CXCR4 and its ligand in vivo mobilizes leukemic cells into the peripheral blood, 
potentially rendering them more susceptible to cytotoxic effects (Juarez et al, 2006). The 
importance of CXCR4 in the context of therapy is further supported by the observation, that 
CXCR4 expression is dynamically up regulated by chemotherapy exposure in ALL cells. Up 
regulation of surface CXCR4 may therefore be considered as a mechanism of chemo resistance 
in acute leukaemias that is potentially reversible with CXCR4-targeted therapy. 
Concerns have been raised regarding potential side effects from CXCR4 inhibition, since 
CXCR4 knockout mice display severe defects in hematopoesis, vascular and cardiac 
development (Nagasawa et al, 1996). However, these defects are related to CXCR4 functions 
in early development, and short-term exposure to AMD3100 for stem cell mobilization does 
not result in any significant toxicity (Broxmeyer et al, 2005). Activity of different CXCR4 
antagonists in animal models for solid tumors (Smith et al, 2004) generalizes the potential 
anti-neoplastic activity and suggests further clinical development of these agents in ALL. It 
is anticipated, that a phase I pediatric study has recently started to study the addition of the 
selective CXCR4 antagonist plerixafor to enhance the conditioning regimen cytotoxicity 
(NCT01068301, www.clinicaltrials.gov). Though the primary goal is to determine the 
maximum tolerated dose (MTD), additional trials are necessary to study the use of 
plerixafor as a complimentary agent with conditioning as well as other chemotherapeutic 
regimens for patients with relapsed or refractory hematologic malignancies. 
3. CD22 immunoconjugates 
The approval of antibody-targeted agents for cancer treatment has provoked increased 
interest in the development of new and improved antibody-mediated therapies. This 
emerging approach centers on targeting cell clusters of differentiation on ALL cells with a 
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monoclonal antibody (mAb), conjugated to a cytotoxic agent. After internalization of the 
antibody-drug complex, vital survival pathways for malignant cells can be blocked or 
dyregulated. Among these, CD22 antibody-targeted agents have more extensively been 
explored with significant preclinical success in models of acute leukemia (Dijoseph et al, 
2004). 
CMC-544 (inotuzumab ozogamicin) is a conjugate of a recombinant humanized antibody 
directed against the CD22 antigen and calicheamicin. After internalization into the target 
cell, calicheamicin binds to DNA in the minor groove in a sequence specific manner, causing 
double-strand DNA breaks followed by apoptotic death. In vitro, CMC-544 binds to CD22 
with subnanomolar affinity and potently inhibits growth of ALL cell lines (Dijoseph et al, 
2007). When administered to xenograft models, CMC-544 prevents engraftment, but also 
induces dose-dependent tumor regression in mice presenting with leukemia. Whereas the 
level of CD22 expression is significantly reduced after incubation with CMC-544, the CD20 
level can be increased (Takeshita et al, 2009). Therefore, sequential administration of 
rituximab increases the cytotoxic effect and supports the rationale for a combination with 
other antibodies. 
Currently, a phase I study is recruiting patients for the aminstration of CMC-544 with or 
without rituximab in relapsed or primary refractory ALL patients (NCT01134575, 
www.clinicaltrials.gov). Preliminary results indicate liver function abnormalities in 25% of 
patients, including periportal fibrosis and venoocclusive disease after allo SCT, among the 
most relevant side effects (Jabbour et al, 2011). Overall, complete response plus complete 
bone marrow response is achieved in more than 50% of the patients. 
Additional phase I studies are soon expected to open, including a single use of CMC-544 in 
refractory ALL patients (NCT01363297, www.clinicaltrials.gov) and a 2 dose level study in 
combination with cyclophosphamide, vincristine, dexamethasone, methotrexate, cytarabine 
in elderly ALL patients (NCT01371630, www.clinicaltrials.gov). 
4. BCL-2 Antisense therapy 
In several clinical studies alterations in the apoptotic threshold were proven to be predictive 
of poor response to treatment and adverse clinical outcome in patients with a variety of 
hematologic malignancies, including acute leukemia. Specifically, the up regulation of the 
BCL-2 family of proteins has been demonstrated to suppress caspase- and non-caspase-
mediated apoptosis mediated by several agents, including -irradiation and chemotherapy 
(Reed et al, 1995). As such, over expression of BCL-2 has been associated with an increased 
risk of relapse in childhood ALL (Hogarth et al, 1999), suggesting the use of factors that 
override the BCL-2 pathway might restore chemo sensitivity in chemo resistant leukemic 
cells.  
Since the discovery of BCL-2, a single antisense oligodeoxynucleotide - Genasense (G3139, 
oblimersen; Genta Inc.) - has been explored. In vitro studies have shown that when 
administered alone or in combination with chemotherapy, G3139 inhibits BCL2 expression, 
resulting in increased tumor cell apoptosis (Webb et al, 1997). Subsequently, its ability to 
effectively reduce BCL-2 protein levels has clearly been demonstrated in a mouse model 
transplanted with leukemia. This effect is correlated with enhanced induction of apoptosis, 
when cells are cultured with the anti-leukemic agents imatinib, daunorubicin, cytarabine 
and etoposide. Mice treated with G3139 have prolonged survival with some showing 
complete tumor regression. Of particular interest is the efficacy of G3139 in STI571 resistant 
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BCR-ABL transformed cells, suggesting its use in clinically acquired STI571 resistance 
(Tauchi et al, 2003). The very low toxicity observed in a phase I study of relapsed acute 
leukemia, demonstrates that G3139 can safely be administered with fludarabine and 
cytarabine salvage chemotherapy (FLAG) without dose limiting toxicity. Common side 
effects of this combination include fever, nausea; emesis, electrolyte imbalance, and fluid 
retention that are not dose limiting. Pharmacokinetics indicates steady-state concentrations 
within 24 hours and is associated with significant down-regulation of BCL-2 mRNA levels 
in 75% of patients (Marcucci et al, 2003). Despite an encouraging result of 45% overall 
survival is achieved, the specific role of G3139 cannot be discriminated from the 
antileukemic activity of FLAG. Based upon the results obtained so far, validation of the 
G3139 efficacy, still needs to be completed with phase II/III trials. 
5. Proteasome inhibitors 
Malignant cells can harbour altered expression of proteasome subunits and their 
distribution between nucleus and cytoplasm can differ from normal cells. Subsequently, the 
ubiquitin-proteasome pathway is involved in malignant cellular hemostasis since it 
regulates the degradation of damaged, oxidized, or misfolded proteins and regulatory 
proteins that govern cell cycle, transcription factor activation, apoptosis, and cell trafficking. 
Key proteins degraded by this pathway include cyclins A, B and E, p21, p27, p53, cJun, cFos, 
IkB, Bcl2, BclX, and MAPK (Laney et al, 1999; Maki et al, 1996). Targeting proteasome 
subunits by proteasome inhibitors offers the possibility to sensitize surviving tumor cells to 
the effect of chemotherapy and to induce apoptosis in tumor cells. 
Bortezomib (Velcade, PS-341; Millenium Pharmaceuticals) is the first proteasome inhibitor 
to be tested in humans and is currently approved for the treatment of relapsed multiple 
myeloma and mantle cell lymphoma. It is a potent and selective, reversible inhibitor of the 
26S proteosome, a key regulatory multi-subunit protease, that controls cell cycle and 
apoptosis (Adams et al, 1998). As in a broad range of tumor cells, bortezomib has 
demonstrated significant activity in ALL cells, inducing apoptosis in vitro and in vivo. 
Additional studies have indicated that it may also potentiate the cytotoxic effects of 
chemotherapy. In particular, it enhances the in vitro cytotoxicity of dexamethasone, 
vincristine, asparaginase, cytarabine, doxorubicin, phenyl butyrate, trichostatin and HA14.1 
(Horton et al, 2006; Sutheesophon et al, 2006). 
A recent phase I clinical study in adults with refractory or relapsed acute leukemias 
indicates the dose of 1.25 mg/m2 to be safely administered on a twice weekly schedule for a 
4 week period (Cortes et al, 2004). This is similar to the currently recommended dose of 1.3 
mg/m2, given in multiple myeloma. Dose limiting toxicity includes orthostatic hypotension, 
nausea, diarrhoea and fluid retention. Evidence of biological activity is demonstrated by 
significant proteasome inhibition. It is anticipated, that few patients have achieved transient 
reduction of bone marrow blasts, with eventual recurrence of the initial blasts, usually 
during the time off therapy. 
Unfortunately, experience in childhood is limited to a phase I trial of bortezomib in pediatric 
patients with solid tumors, showing minimal toxicity. Since it has non-overlapping toxicities 
with myelosuppressive agents used to treat ALL and promising in vitro activity, further 
investigation of bortezomib in this setting is warranted, particularly in studies with 
multimodal chemotherapy. 
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6. Inhibitors of -secretase 
The detection of NOTCH1 gain-of-function mutations in more than 50% of T-cell ALL 
patients has attracted much interest in the understanding of its role in the molecular 
pathogenesis of this leukemic subtype. Although expression of an activated NOTCH1 allele 
has been shown to cause T-cell leukemia in mice, the molecular mechanism for cellular 
transformation is largely unknown. However, the identification of c-myc as a direct and 
critical NOTCH1 target gene (Weng et al, 2004) has urged the screening and development of 
NOTCH1 pathway therapeutics. 
The NOTCH1 inhibitor MK-0752 (Merck & Co.) has been developed for the treatment of 
Alzheimer’s disease, since it cleaves amyloid precursor protein and prevents the formation 
of amyloid ß-peptides (Evin et al, 2006). Its activity in leukemia is demonstrated by the 
conservation of the NOTCH1 receptor within the transmembrane domain, preventing the 
release of the NOTCH intracellular domain, and thereby suppressing the transcription of 
target genes. This results in the arrest of cells in G0/1 , reduces viability, and increases 
apoptosis (DeAngelo et al, 2006). In a phase I trial of adult and pediatric patients with T-cell 
malignancies MK-0752 has been shown to be well-tolerated with diarrhoea being the dose-
limiting toxicity. Measurements of -secretase inhibition have shown a 24-69% decrease in 
plasma Abeta40 peptide levels compared to predose levels (DeAngelo et al, 2006). Only one 
patient with a NOTCH1 activating mutation has achieved a significant reduction of a 
mediastinal mass at the end of the treatment, but has subsequently progressed.  
Currently, an additional phase I study is examining the safety of a newer NOTCH1 inhibitor 
with improved biological availability (PF-03084014, Pfizer; NCT01068301, 
www.clinicaltrials.gov) in adult patients with relapsed T-ALL. 
7. Heat-shock-protein antagonists 
Heat shock protein 90 (Hsp90) is currently receiving considerable attention as a potential 
anticancer drug target. It is a molecular chaperone that regulates structural folding and 
active configuration of a variety of signal transduction and cell cycle regulatory proteins, 
including tyrosine and serine kinases such as c-src and Akt (Isaacs et al, 2003; Hawkins et al, 
2005). Inhibition of Hsp90 disrupts the folding of these proteins, thus increasing their 
susceptibility to ubiquitination and proteosomal degradation. Although the exact 
mechanism by which Hsp90 inhibitors kill tumor cells remain to be defined, the ability to 
abrogate the AKT and BCR-ABL pathways makes these compounds particularly attractive 
for ALL therapy. 
17-allylamino-17-demethoxygeldanamycin (17-AAG) is a toxic derivative of geldanamycin 
and is undergoing clinical examination as it has significant Hsp90-dependent antitumor 
activity and a favorable toxicity profile (Goetz et al, 2005). Following exposure to 17-AAG 
results in a rapid decrease of AKT phosphorylation and total AKT protein levels in pediatric 
ALL patients. This effect can be relevant when 17-AAG is combined with drugs that induce 
AKT activation, such as arsenic trioxide (Pelicano et al, 2006). Sequential administration 
causes rapid decline of phosphorylated AKT, increasing the number of cells accumulating in 
G0/1 phase as well as the rate of cleaved caspase-3. 
Beyond the effect of 17-AAG on AKT function, BCR-ABL has also been shown to be a client 
protein for Hsp90 (Gorre et al, 2002). Treatment with 17-AAG results in significant down-
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regulation of intracellular levels of BCR-ABL, followed by a decrease in cell survival and the 
induction of apoptosis. Of interest is the effect on imatinib mesylate-resistant cells, in which 
sensitivity to imatinib can be restored. 
Based on this selective toxicity, 17-AAG has been examined in phase I and II clinical trials in 
patients with acute myeloid and chronic lymphatic leukemia. These studies have shown that 
17-AAG is reasonably well tolerated, with transient elevation of serum transaminases, 
nausea, vomiting, and diarrhoea being dose-limiting when this agent is administered as a 
60-minute infusion on a weekly schedule. Further studies are required to determine 
tolerability and effectiveness in leukemic patients. 
8. Resveratrol 
Recently, several natural or dietary substances have been shown to have antineoplastic 
activity. Much attention has been paid to the polyphenolic phytoalexin resveratrol (3,5,4’-
trihydroxy-trans-stilbene), since it inhibits events associated with tumor initiation, 
promotion and progress (Jang et al, 1997). Potentially, it inhibits free-radical formation and 
reduces oxidative and mutagenic stress (Aggarwal et al, 2004). Subsequently, resveratrol 
suppresses the growth of transformed cells and induces apoptosis through interaction with 
kinase pathways and activation of the caspase cascade (Bernhard et al, 2000). 
In leukemic cells resveratrol arrests cells in the S-phase of the cell cycle. A mechanism, by 
which the replication machinery is arrested, is demonstrated by the inhibition of the 
ribonucleotide reductase in murine lymphoblastic leukemic cells. Additionally, both the 
NOTCH and the PI3K/AKT pathway are inhibited at higher concentrations of resveratrol. 
This is modulated by the activation of signalling systems, such as p53, p21waf-1 and Bax 
(Cecchinato et al, 2007). Also, resveratrol has been shown to induce mitochondrial 
depolarization and subsequent activation of downstream caspases associated with the 
intrinsic apoptotic pathway (Dorrie et al, 2001; Fontecave et al, 1998). Independence of Fas- 
and TNF signalling in resveratrol-induced apoptosis might be a desirable property of a 
potential new therapeutic agent, since tumor cells develop strategies to escape Fas-mediated 
apoptosis (Bernhard et al, 2000). 
Preliminary results of a phase II study of the synthetic resveratrol derivative SRT501 
(GlaxoSmithKline) in multiple myeloma patients reveal, that administration of this 
formulation is limited by the development of the acute renal failure (NCT00920556, 
www.clinicaltrials.gov). Whereas this complication might be restricted to the underlying 
disease, tolerability and efficacy of resveratrol in leukemic patients still remain to be 
clarified in further clinical investigations. 
9. Fms-like tyrosine kinase-3 inhibitors 
The fms-like tyrosine kinase-3 (FLT3) is a member of the class III receptor tyrosine kinase 
family and is largely expressed along with CD34 and CD117 in immature hematopoetic 
progenitor cells. Knock-out mice are associated with deficiencies in B-cell lymphopoesis and 
reconstitution of both T cells and myeloid cells after BMT, indicating a crucial role of FLT3 
in the development of multipotent hematopoetic and lymphoid cells. 
Similarly, FLT3 has been implicated in the pathogenesis of leukemia (Carow et al, 1996). In 
addition to the near-universal FLT3 expression in adult precursor B-ALL, gene expression 
analysis have shown, that the highest levels of FLT3 expression occur in infant and 
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childhood ALL with rearrangement of the MLL gene and in ALL patients with 
hyperdiploidy (Armstrong et al, 2002, 2004); . In vitro studies have shown that coexpression 
of FLT3 ligand and activating mutations on the FLT3 gene can constitutively activate 
downstream targets. These include signal transducers and activators of transcription 
(STAT), MAPK, and AKT pathways that regulate proliferation, differentiation, and survival 
(Mizuki et al, 2000). Considering the worse prognosis of MLL patients and understanding 
the molecular mechanism of FLT3, has prompted the development of specific FLT3 
inhibitors. 
Small-molecular FLT3 inhibitors have initially been developed for AML, in which FLT3 
mutations represent the most common somatic genetic alteration. FLT3 inhibitors induce 
significant cytotoxic responses, and several of these agents have been tested in adult trials of 
AML (Fiedler et al, 2005; Smith et al, 2004). FLT3 inhibitors are well tolerated; toxicities 
include mild nausea, emesis and generalized weakness with the highest doses administered. 
In MLL-rearranged ALL, treatment with the FLT3 inhibitor PKC-412 (Midostaurin, Novartis 
Pharmaceuticals) has proved to be cytotoxic to Ba/F3 cells dependent upon activating 
mutations of FLT3 (Armstrong et al, 2003). Similarly, ALL with high hyperdiploidy and t 
(4;11), has shown pronounced apoptotic responses to treatment with CEP-701 (Lesaurtinib, 
Cephalon) (Brown et al, 2005). Synergistic effects have not been noted, when FLT3 inhibitors 
are used simultaneously or immediately following exposure to cytarabine, daunorubicin, 
mitoxantrone or etoposide. These effects might be of interest, if used to overcome rapid 
development of resistance to FLT3 inhibitors (Levis et al, 2004). Of note, pretreatment with 
CEP-701 in combination with cytarabine may act antagonistically, due to its cell-cycle 
inhibitory effect in AML. 
In MLL-rearranged ALL with wild type FLT3, FLT3 ligand induces quiescence and 
chemoresistance that can be overcome by FLT3 inhibition (Furuichi et al, 2007). It is possible 
that ligation of FLT3 in these ALL cases contributes to the poor response to chemotherapy 
by activating quiescence and self-renewal functions. It is therefore worth examining the 
ability of FLT3 inhibitors to reverse this response and increase chemosensitivity in this 
particularly difficult to treat group of patients. More specific FLT3 targeting has recently 
been developed by the application of anti-FLT3 antibodies (Piloto et al, 2006). IMC-NC7 
consistently inhibits FLT3 phosphorylation, whereas IMC-EB10 stimulates its activation. 
Both treatments prolong survival and/or reduced engraftment of leukemic cells in a 
NOD/SCID mouse model, mainly through the recruitment of the host’s immune system 
against targeted cells, independently of receptor activation.  
A phase I/II clinical trial is currently recruiting patients that will evaluate the safety, 
tolerability, clinical response, pharmacokinetics and pharmacodynamics of PKC-412 in 
children who have relapsed or refractory acute leukemias, including MLL-rearranged ALL 
(NCT00866281, www.clinicaltrials.gov). 
10. Farnesyl transferase inhibitors 
Inhibitors of farnesyl transferase (FTI) have originally been developed to prevent 
attachment of intracellular Ras to the inner leaflet of the plasma membrane and, therefore, 
transduction of proliferative and survival signals (Gelb et al, 1997). Subsequent studies, 
however, have suggested that the cytotoxic actions of FTIs might also involve oncoproteins 
other than Ras, such as RhoB and members of phosphoinositide 3/OH kinase (PI3K)/AKT-2 
www.intechopen.com
 
Novel Aspects in Acute Lymphoblastic Leukemia 
 
172 
pathway (Lebowitz et al, 1998), suggesting that the mechanism of action of FTIs is 
significantly more complex than initially presumed. 
Results of in vitro exposure of several leukemic cells provide evidence for the efficacy of FTIs 
in suppressing tumor cell proliferation. Particularly, the nonpeptidomimetic enzyme-
specific inhibitor R115777 (Tipifarnib, Johnson & Johnson) has been shown to decrease 
proliferation and sensitize apoptosis to chemotherapy-induced cell death. A phase I trial of 
R115777 in adults with poor-risk acute leukemia provides first evidence for in vivo efficacy. 
29% of the 34 evaluable patients have shown a clinical response, including 2 patients with 
complete remission (Karp et al, 2001). Dose limiting toxicities on various schedules include 
central neurotoxicity and reversible nausea, renal insufficiency, polydipsia, paresthesia and 
myelosuppression. 
Of note is the novel, orally active FTI SCH66336 (Lonafarnib, Schering-Plough), which 
competes with the enzyme for the CAAX portion of Ras and induces apoptosis in acute 
myeloid leukemia. It might be particularly attractive for a combination therapy with STI571, 
since it has been shown to inhibit the proliferation of STI571-resistant BCR-ABL-positive cell 
lines and synergize for the induction of apoptosis (Borthakur et al, 2006; Hoover et al, 2002). 
11. DNA methylase inhibitors 
Aberrant DNA methylation of multiple promoter CpG islands is frequently observed in 
patients with ALL both at initial presentation and at the time of relapse. Indeed these 
methylation marks are stable in over 70% of patients with ALL at the time of relapse. 
Importantly, methylation of specific molecular pathways has been associated with an 
extremely poor prognosis in patients with ALL. This has been demonstrated in the aberrant 
methylation of the promotor region within tumor suppressor genes such as the fragile 
histidine triad (FHIT) of members of the cell cycle pathway such as p73, the cyclin 
dependent kinase inhibitors p57KIP2 and p15 (Bueso-Ramos et al, 2005). Pharmacologic 
modification of aberrant methylation can therefore be an attractive approach to regulate 
leukemic cell proliferation. 
Recently, the pyrimidine nucleoside analog 5-Aza-2’-deoxycytidine (decitabine/Daco-gene, 
SuperGen) has received much interest as a strong hypomethylating agent with clinical 
activity in myelodysplastic syndrome, and acute and chronic myelogeous leukemia (Richel 
et al, 1991). In vitro exposure of decitabine results in hypomethylation and reactivation of 
putative tumor suppressor genes. As a result, low concentrations of decitabine stimulate 
cellular differentiation, whereas high concentrations directly interfere with DNA synthesis 
and mediate cytotoxicity in acute leukemias (Pinto et al, 1984). Combination therapy with 
cytarabine achieves complete remission in the majority of patients in a clinical trial of ALL 
(Richel et al, 1991). Analysis of cell membrane markers shows a loss of the early 
differentiation antigens CD34 and CD33 in leukemic bone marrow cells, which is suggestive 
of leukemic cell differentiation. Addition of HDACIs might synergize in controlling gene 
transcription as has successfully been shown in a clinical trial for t(8;14) AML (Klisovic et al, 
2003). 
Temozolomide (Temodal, Schering-Plough) is a second-generation oral alkylating agent 
with DNA methylating properties. Although the exact mechanism for methylation is not 
fully elucidated, it results in an active mismatch-repair pathway with consequent DNA 
strand breakage and apoptosis (D’Atri et al, 1998). Temozolomide is well tolerated when it 
is administered as a single agent (Seiter el al, 2002). Because of the chance to deplete O6-
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alkylguanine DNA alkyltransferase levels, a potential mechanism of drug resistance, 
temozolomide should be administered in an extended low-dose schedule, as has been 
suggested in a clinical trial of malignant gliomas (Khan et al, 2002). 
12. Histone deacetylase inhibitors 
Epigenetic changes to promoter regions have been identified in recent years as important 
factors in the pathogenesis of acute leukemia. They include DNA modifications that regulate 
chromatin structure and change gene expression without altering the nucleotide sequence. 
A promising new therapeutic strategy is aimed at removal of acetyl groups from histone 
proteins as well as other non-histone protein targets with histone deacetylation inhibitors 
(HDACIs), which results in chromatin remodeling that permits re-expression of silenced 
tumor suppressor genes in cancer cells (Brown et al, 2002). This in turn, can potentially 
result in cellular differentiation, inhibition of proliferation and/or apoptosis. 
Several classes of HDACIs are currently under development for treatment of leukemia, 
including the short-chain fatty acids sodium phenylbutyrate and valproic acid, the 
hydroxamic acids suberoylanilide hydroxamic acid (SAHA, Vorinostat, Merck & Co.), FK-
228 (Depsipeptide, Gloucester Pharmaceuticals) and LBH589 (Panobinostat, Novartis 
Pharmaceuticals), and the benzamides MS-275 and C1-994.  
In vitro studies have demonstrated that HDACIs trigger maturation, when administered at 
low concentrations, whereas at higher concentrations, apoptosis is induced. The factors that 
determine whether HDACIs engage apoptosis versus differentiation remain the subject of 
investigation, but they may involve the induction of death receptors such as Fas- and tumor-
necrosis-factor-related apoptosis-inducing ligand (TRAIL) (Bernhard et al, 2001; Inoue et al, 
2004), the production of reactive oxygen species, which leads to mitochondrial disruption 
(Bernhard et al, 2001), independently of activation of caspase-8 or -3, followed by 
internucleosomal DNA fragmentation. Specifically in Philadelphia chromosome-positive 
(Ph+) ALL, HDACIs reduce viability and increase expression of the apoptosis associated 
proteins FANCG, FOXO3A, GADD45A, GADD45B and GADD45G (Scuto et al, 2008). If 
HDACIs are used at lower concentrations, they induce either G0/1 or G2-M arrest. These 
events are accompanied by induction of p53 and p21WAF1, and down-regulation of cell cycle-
promoting proteins, including cyclin D1 and D2. 
In vivo FK-228 effectively inhibits HDAC in patients with chronic lymphatic leukemia (CLL) 
and acute myeloid leukemia (AML) (Byrd et al, 2005), but its use in the current schedule of 
administration is limited by progressive constitutional symptoms. Dose-limiting toxicities 
include anorexia, dehydration, diarrhoea, and fatigue. Several patients have evidence of 
anti-tumor activity following treatment, but no partial or complete response is noted. Both, 
SAHA and LBH589, have been reported to be tolerable for short- and long-term application 
in phase I clinical trials of adult refractory hematological malignancies (Garcia-Manero et al, 
2008). Based on the safety and efficacy demonstrated in phase I/II trials, a single HDACI 
compound, SAHA, has been approved for the treatment of cutaneous T-cell lymphoma, 
after demonstrating activity in heavily pre-treated patients. 
Regarding childhood ALL data, a recent phase I study of vorinostat has just been published. 
Drug disposition and tolerance in children is similar to that observed in adult patients, 
whereas the maximum tolerated dose (MTD) seems to be lower due to liver dysfunction. 
Furthermore, a phase II study is reported as currently recruiting participants (NCT00882206, 
www.clinicaltrials.gov). Specifically, this trial is investigating the use of decitabine and 
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vorinostat together with combination chemotherapy in treating patients with 
relapsed/refractory ALL or lymphoblastic lymphoma. 
13. Mammalian target of rapamycin inhibitors 
The mammalian target of rapamycin (mTOR) is a critical effector in cell-signalling 
pathways, such as the PI3K/AKT transduction pathway, that are up regulated in malignant 
transformed cells (Dann et al, 2006). After activation of G-protein coupled receptors by 
various growth factors, mTOR mediates the phosphorylation of the 70 kDa S6 ribosomal 
protein kinase and the initiation factor 4E-binding protein 1 (Vignot et al, 2005). 
Subsequently, activated cyclin D1, CDK4, and Rb initiate the G0/1 to S phase progression. 
Accordingly, targeting the mTOR signalling pathway has extensively been analyzed for 
suppression of leukemic cell proliferation. 
Inhibitors of mTOR include rapamycin (Sirolimus, Wyeth Pharmaceuticals) and the second 
generation analogs RAD001 (Everolimus, Novartis Pharmaceuticals), and CCI-779 
(Temsirolimus, Wyeth Pharmaceuticals). Rapamycin was initially developed as 
immunosuppressive agent and was the first inhibitor to be used in a clinical setting for 
leukemic therapy. Rapamycin induces apoptosis in precursor B ALL lines in vitro and has in 
vivo activity in transgenic mice with pre-B leukemia/lymphoma (Brown et al, 2003). CCI-779 
inhibits the growth of adult human ALL on bone marrow layers and reduces the number of 
blasts in the peripheral-blood and the degree of organ infiltration in human ALL engrafted 
NOD/SCID mice (Teachey et al, 2006). RAD001 reduces tumor mass in vivo, conferring 
prolonged survival of NOD/SCID mice engrafted with childhood ALL (Crazzolara et al, 
2009). Mechanistic insight demonstrates the induction of autophagy in the absence of 
apoptosis, which is particular interesting in ALL, since resistance to current chemotherapies, 
such as dexamethasone, has been linked to certain defects in the apoptotic machinery. 
Phase I trials in patients with various cancers show that mTOR inhibitors when used as 
monotherapy are well tolerated in humans, with little nephrotoxicity and neurotoxicity 
(Calne et al, 1989). They may further cause hyperlipidemia, mild myelosuppression, 
hypertension, skin rashes and mucositis. However, the toxicities of combining mTOR 
inhibitors with conventional cytotoxic agents have not been fully explored in both 
preclinical and clinical studies. Based on the preclinical work, a number of clinical trials 
evaluating the efficacy of mTOR inhibitors in ALL as single agents and in combination with 
other agents have been performed are still on-going (NCT01162551, www.clinicaltrials.gov). 
Two phase I/II trials of MTIs in patients with relapsed or refractory malignances, including 
one patient each with ALL, have shown that both patients have tolerated therapy, but 
neither have had an objective response. A recent interim result of an on-going phase 1 trial 
of sirolimus in children reveals that 3 of 7 patients relapsed/refractory ALL have stable 
disease. 
14. Cyclin dependent kinase inhibitors 
Loss of p16 (INK4A) in hematopoietic stem cells is associated with enhanced self-renewal 
capacity and might facilitate progression of damaged stem cells into pre-cancerous cells that 
give rise to leukemia (Bhojwani et al, 2006). Based on higher frequency of p16 (INK4A) 
deletions in relapsed ALL, inhibitors of cyclin dependent kinases (CDKs) have been  
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(R= relapse, eto= etoposide, ara-c= cytarabine, rit= rituximab, cpm= cyclophosphamide, vin= 
vincristine, dex= dexamethasone, flu= fludarabine, mit= mitoxantrone, asp= asparaginase, dau= 
daunorubicine, dox= doxorubicine, mer= mercaptopurine, vor= vorinostat, pre= predinison, mtx= 
methotrexate, ima= imatinib) 
Table 1. Active and completed clinical trials with novel therapeutic targets for ALL.  
investigated for their antileukemic potential. Among them, the synthetic flavone derivative 
flavopiridol (Alvocidib, L86-8275; Behringwerke) is the first to undergo human trials. 
Flavopiridol binds to the adenosine triphosphate (ATP) site of CDK, thereby reducing the 
activity of CDK1, CDK2, CDK4, CDK6, and CDK7, leading to cell cycle arrest in G0/1 and G2 
(Sedlacek et al, 2001). In addition, flavopiridol disrupts the CDK9/cyclin T complex 
resulting in reduced phosphorylation of the carboxyl-terminal domain of RNA Pol-II and 
subsequent inhibition of mRNA synthesis (Chao et al, 2000). Consequently, short lived anti-
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apoptotic proteins such as MCL-1 and BCL-2 and those that are cell cycle dependent such as 
cyclin D1 are depleted. This could provide an explanation for increased apoptosis observed 
following exposure to flavopiridol. 
Pre-clinical studies have demonstrated the efficacy of flavopiridol in primary ALL samples. 
A phase I clinical trial of flavopiridol followed by cytarabine and mitoxantrone in patients 
with relapsed or refractory adult ALL has shown moderate biological and clinical benefits 
(Karp et al, 2005). Dose-limiting toxicities include sustained neutropenia, diarrhoea and 
mucositis. As suggested by a CLL clinical trial, a more sustained schedule of flavopiridol 
might be needed to improve the clinical response rate, without increasing neutropenia as the 
dose-limiting toxicity. 
15. Conclusion 
The future of treatment optimization resides in exploring the molecular pathways involved 
in the pathogenesis of leukemia and in understanding the pharmacogenomic factors of the 
host. If successful, new protein products can be generated that are administered as targeted 
therapy with a narrow therapeutic window. A primary example of such therapy is given by 
the inhibitor of tyrosine kinase imatinib, which is the first anti-cancer agent that specifically 
targets the genetic defect underlying Philadelphia positive ALL. Although imatinib is 
currently implemented in the treatment of BCR/ABL positive ALL and has improved 
overall survival, its use as single agent should not be overestimated. In fact, imatinib is 
targeting a specific molecular pathway that regulates gene transcription, cell proliferation or 
survival, but not the principal genetic lesion. Accordingly, imatinib produces relatively 
short-lived remission in Ph+ ALL as single agent, but has the potential to improve survival, 
when combined with current chemotherapy. Similarly, it is likely that the key to the 
successful use of other molecular targeted therapies will be in the careful combination of 
novel agents with traditional chemotherapeutic regimes and/or with other molecularly 
targeted agents. Indeed many agents, including imatinib, flavopiridol and oblimersen are 
being tested in combination with standard chemotherapy, while imatinib is also being 
combined with inhibitors of farnesyl transferase, HDAC, cyclin dependent kinases, HSP90 
and BCL-2. Ultimately, these combinations need to be based on a thorough understanding 
of the molecular pathways driving disease in each patient. Additionally, pharmacogenomic 
information will be essential for the development of optimal effective treatment regimes 
with minimal side effects. 
16. Acknowledgment 
This work was supported by the Children’s Cancer Aid Society Tirol and Vorarlberg. 
17. References 
Adams J, Behnke M, Chen SW, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, 
Plamondon L, Stein RL. (1998). Potent and selective inhibitors of the proteasome: 
Dipeptidyl boronic acids. Bioorganic & Medicinal Chemistry Letters, Vol.8, No.4, 
pp.333-338 
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. (2004). Role of 
resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. 
Anticancer Research, Vol.24, No.5A, pp.2783-2840 
www.intechopen.com
 
Novel Therapeutic Targets in ALL Therapy 
 
177 
Armstrong SA, Staunton JE, Silverman LB, Pieters R, de Boer ML, Minden MD, Sallan SE, 
Lander ES, Golub TR, Korsmeyer SJ. (2002). MLL translocations specify a distinct 
gene expression profile that distinguishes a unique leukemia. Nature Genetics, 
Vol.30, No.1, pp.41-47 
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, den Boer ML, Pieters R, 
Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. (2003). 
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene 
expression based classification. Cancer Cell, Vol.3, No.2, pp.173-183 
Armstrong SA, Mabon ME, Silverman LB, Li AH, Gribben JG, Fox EA, Sallan SE, Korsmeyer 
SJ. (2004). FLT3 mutations in childhood acute lymphoblastic leukemia. Blood, 
Vol.103, No.9, pp.3544-3546 
Barr RD, Sala A. Osteonecrosis in children and adolescents with cancer. (2008). Pediatric 
Blood & Cancer, Vol.50, No.2, pp.483-485 
Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, Greil R, Kofler R, Csordas A. 
(2000). Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis 
in CEM-C7H2 acute leukemia cells. Cell Death and Differentiation, Vol.7, No.9, 
pp.834-842 
Bernhard D, Skvortsov S, Tinhofer I, Hubl H, Greil R, Csordas A, Kofler R. (2001). Inhibition 
of histone deacetylase activity enhances Fas receptor-mediated apoptosis in 
leukemic lymphoblasts. Cell Death and Differentiation, Vol.8, No.10, pp.1014-1021 
Bhojwani D, Kang HN, Moskowitz NP, Min DJ, Lee H, Potter JW, Davidson G, Willman CL, 
Borowitz MJ, Belitskaya-Levy I, Hunger SP, Raetz EA, Carroll WL. (2006). Biologic 
pathways associated with relapse in childhood acute lymphoblastic leukemia: a 
Children's Oncology Group study. Blood, Vol.108, No.2, pp.711-717 
Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl 
S, Sugrue M, Cortes J. (2006). Pilot study of lonafarnib, a farnesyl transferase 
inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated 
phase that is resistant or refractory to imatinib therapy. Cancer, Vol.106, No.2, 
pp.346-352 
Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li XX, 
Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF. (2005). 
Rapid mobilization of murine and human hematopoietic stem and progenitor cells 
with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine, Vol.201, No.8, 
pp.1307-1318 
Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. (2005). FLT3 inhibition 
selectively kills childhood acute lymphoblastic leukemia cells with high levels of 
FLT3 expression. Blood, Vol.105, No.2, pp.812-820 
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu SJ, Sklenar AR, 
Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan 
KK, Grever MR. (2005). A phase 1 and pharmacodynamic study of depsipeptide 
(FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 
Vol.105, No.3, pp.959-967 
Bueso-Ramos C, Xu YL, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-
Manero G. (2005). Protein expression of a triad of frequently methylated genes, p73, 
p57(Kip2), and p15, has prognostic value in adult acute lymphocytic leukemia 
independently of its methylation status. Journal of Clinical Oncology, Vol.23, No.17, 
pp.3932-3939 
www.intechopen.com
 
Novel Aspects in Acute Lymphoblastic Leukemia 
 
178 
Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. (2000). Blood-
derived nurse-like cells protect chronic lymphocytic leukemia B cells from 
spontaneous apoptosis through stromal cell-derived factor-1. Blood, Vol.96, No.8, 
pp.2655-2663 
Calne RY, Lim S, Samaan A, Collier DSJ, Pollard SG, White DJG, Thiru S. (1989). Rapamycin 
for Immunosuppression in Organ Allografting. Lancet, Vol.2, No.8658, pp.227 
Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, Witte L, Borowitz MJ, 
Civin CI, Small D. (1996). Expression of the hematopoietic growth factor receptor 
FLT3 (STK-1/Flk2) in human leukemias. Blood, Vol.87, No.3, pp.1089-1096 
Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet GV, Comi P. 
(2007). Resveratrol-induced apoptosis in human T-cell acute lymphoblastic 
leukaemia MOLT-4 cells. Biochemical Pharmacology, Vol.74, No.11, pp.1568-1574 
Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, 
Price DH. (2000). Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. Journal 
of Biological Chemistry, Vol.25, No.37, pp.28345-28348 
Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, 
Patel G, Guerciolini R, Wright J, Kantarjian H. (2004). Phase I study of bortezomib 
in refractory or relapsed acute leukemias. Clinical Cancer Research, Vol.10, No.10, 
pp.3371-3376 
Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, Mohle R, Meister B. (2001). 
High expression of the chemokine receptor CXCR4 predicts extramedullary organ 
infiltration in childhood acute lymphoblastic leukaemia. British Journal of 
Haematology, Vol.115, No.3, pp.545-553 
Crazzolara R, Cisterne A, Thien M, Hewson J, Bradstock KF, Bendall LJ. (2009). The mTOR 
inhibitor RAD001 (Everolimus) improves survival in preclinical models of primary 
human ALL. Blood, Vol.113, No.14, pp.3297-3306 
Dann SG, Thomas G. (2006). The amino acid sensitive TOR pathway from yeast to 
mammals. Febs Letters, Vol.580, No.12, pp.2821-2829 
DeAngelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, Dallob A, Matthews C, 
Stone J, Freedman SJ, Aster J. (2006). A phase I clinical trial of the notch inhibitor 
MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) 
and other leukemias. Journal of Clinical Oncology, Vol.24, No.18, pp.357S 
DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, 
Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, 
Damle NK. (2004). Antibody-targeted chemotherapy with CMC-544: a CD22-
targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid 
malignancies. Blood, Vol.103, No.5, pp.1807-1814 
DiJoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. (2007). Therapeutic 
potential of CD22-specific antibody-targeted chemotherapy using inotuzumab 
ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. 
Leukemia, Vol.21, No.11, pp.2240-2245 
Dorrie J, Gerauer H, Wachter Y, Zunino SJ. (2001). Resveratrol induces extensive apoptosis 
by depolarizing mitochondrial membranes and activating caspase-9 in acute 
lymphoblastic leukemia cells. Cancer Research; , Vol.61, No.12, pp.4731-4739 
Evin G, Sernee MF, Masters CL. (2006). Inhibition of gamma-secretase as a therapeutic 
intervention for Alzheimer's disease - Prospects, limitations and strategies. Cns 
Drugs, Vol.20, No.5, pp.351-372 
www.intechopen.com
 
Novel Therapeutic Targets in ALL Therapy 
 
179 
Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, 
Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, 
Scigalla P, Berdel WE, Hossfeld DK. (2005). A phase 1 study of SU11248 in the 
treatment of patients with refractory or resistant acute myeloid leukemia (AML) or 
not amenable to conventional therapy for the disease. Blood, Vol.105, No.3, pp.986-
993 
Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. (1998). Resveratrol, a 
remarkable inhibitor of ribonucleotide reductase. Febs Letters, Vol.421, No.3, pp.277-
279 
Freycon F, Trombert-Paviot B, Casagranda L, Bertrand Y, Plantaz D, Marec-Berard P. (2008). 
Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over 
time: A follow-up of patients included in the childhood cancer registry of the 
Rhone-Alpes Region in France (ARCERRA). Pediatric Blood & Cancer, Vol.50, No.6, 
pp.1213-1220 
Furuichi Y, Goi K, Inukai T, Sato H, Nemoto A, Takahashi K, Akahane K, Hirose K, Honna 
H, Kuroda I, Zhang X, Kagami K, Hayashi Y, Harigaya K, Nakazawa S, Sugita K. 
(2007). Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged 
leukemia cells into quiescence resistant to antileukemic agents. Cancer Research, 
Vol.67, No.20, pp.9852-9861 
Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, 
Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, 
Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. 
(2008). Phase 1 study of the histone deacetylase inhibitor vorinostat 
(suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias 
and myelodysplastic syndromes. Blood, Vol.111, No.3, pp.1060-1066 
Gelb MH. (1997). Protein biochemistry - Protein prenylation, et cetera: Signal transduction in 
two dimensions. Science, Vol.275, No.5307, pp.1750-1751 
Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, 
Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. (2005). Phase I trial of 17-
allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Journal of 
Clinical Oncology, Vol.23, No.6, pp.1078-1087 
Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. (2002). BCR-ABL point 
mutants isolated from patients with imatinib mesylate-resistant chronic myeloid 
leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock 
protein 90. Blood, Vol.100, No.8, pp.3041-3044 
Hawkins LM, Jayanthan AA, Narendran A. (2005). Effects of 17-allylamino-17-
demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia 
(ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric 
Research, Vol.57, No.3, pp.430-437 
Hogarth LA, Hall AG. (1999). Increased BAX expression is associated with an increased risk 
of relapse in childhood acute lymphocytic leukemia. Blood, Vol.93, No.8, pp.2671-
2678 
Hoover RR, Mahon FX, Melo JV, Daley GQ. (2002). Overcoming STI571 resistance with the 
farnesyl transferase inhibitor SCH66336. Blood, Vol.100, No.3, pp.1068-1071 
Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. (2006). 
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. 
Cancer Chemotherapy and Pharmacology, Vol.58, No.1, pp.13-23 
www.intechopen.com
 
Novel Aspects in Acute Lymphoblastic Leukemia 
 
180 
Inoue S, MacFarlane M, Harper N, Wheat LMC, Dyer MJS, Cohen GM. (2004). Histone 
deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-
induced apoptosis in lymphoid malignancies. Cell Death and Differentiation, Vol.11, 
pp.S193-S206 
Isaacs JS, Xu WP, Neckers L. (2003). Heat shock protein 90 as a molecular target for cancer 
therapeutics. Cancer Cell, Vol.3, No.3, pp.213-217 
Jabbour E, O'Brien SM, Thomas DA, Ravandi F, York S, Kwari M, Faderl S, Kadia TM, 
Wilson C, Tarnai R, Advani AS, Garcia-Manero GC, Cortes JE, Kantarjian H. (2011) 
Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to 
calicheamycin, produces complete response (CR) plus complete marrow response 
(mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia 
(ALL). Journal of Clinical Oncology, Vol.29, Suppl; abstr 6507 
Jang MS, Cai EN, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, 
Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. (1997). Cancer 
chemopreventive activity of resveratrol, a natural product derived from grapes. 
Science, Vol.275, No.5297pp. 218-220 
Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. (2003). Effects of inhibitors of the chemokine 
receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia, Vol.17, 
No.7, pp.1294-1300 
Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock 
KF, Bendall LJ. (2007). CXCR4 antagonists mobilize childhood acute lymphoblastic 
leukemia cells into the peripheral blood and inhibit engraftment. Leukemia, Vol.21, 
No.6, pp.1249-1257 
Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. (2002). A phase II study of 
extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology, 
Vol.4, No.1, pp.39-43 
Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, 
Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. 
(2003). Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, 
apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in 
AML1/ETO-positive leukemic cells. Leukemia, Vol.17, No.2, pp.350-358 
Laney JD, Hochstrasser M. (1999). Substrate targeting in the ubiquitin system. Cell, Vol.97, 
No.4, pp.427-430 
Lebowitz PF, Prendergast GC. (1998). Non-Ras targets of farnesyltransferase inhibitors: 
focus on Rho. Oncogene, Vol.17, No.11, pp.1439-1445 
Levis M, Pham R, Smith BD, Small D. (2004). In vitro studies of a FM inhibitor combined 
with chemotherapy: sequence of administration is important to achieve synergistic 
cytotoxic effects. Blood, Vol.104, No.4, pp.1145-1150 
Maki CG, Huibregtse JM, Howley PM. (1996). In vivo ubiquitination and proteasome-
mediated degradation of p53. Cancer Research, Vol.56, No.11, pp.2649-2654 
Marcucci G, Byrd JC, Dai GW, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, 
Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zvviebel JA, Kraut EH, 
Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. (2003). Phase 1 and 
pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in 
combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 
Vol.101, No.2, pp.425-432 
www.intechopen.com
 
Novel Therapeutic Targets in ALL Therapy 
 
181 
Messinger Y, Reaman GH, Ek O, Uckun FM. (1999). Evaluation of temozolomide in a SCID 
mouse model of human B-cell precursor leukemia. Leukemia & Lymphoma, Vol.33, 
No.3-4, pp.289-293 
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning R, Kratz-Abers 
K, Serve S, Steur C, Buchner T, Kienast J, Kanakura Y, Berdel WE, Serve H. (2000). 
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 
32D cells mediated by the Ras and STAT5 pathways. Blood, Vol.96, No.12, pp.3907-
3914 
Muller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T, Murphy E, 
Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. (2001). 
Involvement of chemokine receptors in breast cancer metastasis. Nature, Vol.410, 
No.6824, pp.50-56 
Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, 
Kikutani H, Kishimoto T. (1996). Defects of B-cell lymphopoiesis and bone-marrow 
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, Vol.382, 
No.6592, pp. 635-638 
Pelicano H, Carew JS, McQueen TJ, Plunkett M, Keating MJ, Huang P. (2006). Targeting 
Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic 
drug combinations with arsenic trioxide and Ara-C. Leukemia, Vol.20, No.4, pp.610-
619 
Piloto O, Nguyen B, Huso D, Kim KT, Li YW, Witte L, Hicklin DJ, Brown P, Small D. (2006). 
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces 
nonobese diabetic/severe combined immunodeficient engraftment of some acute 
lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Research, 
Vol.66, No.9, pp.4843-4851 
Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Difiore PP. (1984). 5-Aza-2'-
Deoxycytidine Induces Terminal Differentiation of Leukemic Blasts from Patients 
with Acute Myeloid Leukemias. Blood, Vol.64, No.4, pp.922-929 
Pui CH, Evans WE. (2006). Drug therapy - Treatment of acute lymphoblastic leukemia. New 
England Journal of Medicine, Vol.354, No.2, pp.166-178 
Pui CH, Robison LL, Look AT. (2008). Acute lymphoblastic leukaemia, Lancet, Vol.371, 
No.9617, pp. 1030-1043 
Reed JC. (1995). Bcl-2 - Prevention of Apoptosis As A Mechanism of Drug-Resistance. 
Hematology-Oncology Clinics of North America, Vol.9, No.2, pp.451-473 
Richel DJ, Colly LP, Kluinnelemans JC, Willemze R. (1991). The Antileukemic Activity of 5-
Aza-2 Deoxycytidine (Aza-Dc) in Patients with Relapsed and Resistant Leukemia. 
British Journal of Cancer, Vol.64, No.1, pp.144-148 
Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P, Pullarkat V, Bhatia R, 
Forman S, Yen Y, Jove R. (2008). The novel histone deacetylase inhibitor, LBH589, 
induces expression of DNA damage response genes and apoptosis in Ph- acute 
lymphoblastic leukemia cells. Blood, Vol.110, No.10, pp.5093-5100 
Sedlacek HH. (2001). Mechanisms of action of flavopiridol. Critical Reviews in Oncology 
Hematology, Vol.38, No.2, pp.139-170 
Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. (2002). Phase I study of 
temozolomide in relapsed/refractory acute leukemia. Journal of Clinical Oncology, 
Vol.20, No.15, pp.3249-3253 
www.intechopen.com
 
Novel Aspects in Acute Lymphoblastic Leukemia 
 
182 
Smith MCP, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. (2004). 
CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer 
Research, Vol.64, No.23, pp.8604-8612 
Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach 
J, Small D. (2004). Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and 
clinical activity in patients with relapsed or refractory acute myeloid leukemia. 
Blood, Vol.103, No.10, pp.3669-3676 
Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y. 
(2006). Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in 
leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced 
by the proteasome inhibitor bortezomib. Acta Haematologica, Vol.115, No.1-2, pp.78-
90 
Takeshita A, Yamakage N, Shinjo K, Ono T, Hirano I, Nakamura S, Shigeno K, Tobita T, 
Maekawa M, Kiyoi H, Naoe T, Ohnishi K, Sugimoto Y, Ohno R. (2009), CMC-544 
(inotuzumab ozogamicin), an anti-CD22 immunoconjugate of calicheamicin, alters 
the levels of target molecules of malignant B-cell. Leukemia, Vol.33, No.7, pp.1329-
1336 
Teachey DT, Obzut DA, Cooperman J, Fang JJ, Carroll M, Choi JK, Houghton PJ, Brown VI, 
Grupp SA. (2006). The mTOR inhibitor CCI-779 induces apoptosis and inhibits 
growth in preclinical models of primary adult human ALL. Blood, Vol.107, No.3, 
pp.1149-1155 
Viana MB, Vilela MNP. (2008). Height deficit during and many years after treatment for 
acute lymphoblastic leukemia in children: A review. Pediatric Blood & Cancer, 
Vol.50, No.2, pp.509-516 
Vitale A, Guarini A, Chiaretti S, Foa R. (2006). The changing scene of adult acute 
lymphoblastic leukemia. Current Opinion in Oncology, Vol.18, No.6, pp.652-659 
Vignot S, Faivre S, Aguirre D, Raymond E. (2005). MTOR-targeted therapy of cancer with 
rapamycin derivatives. Annals of Oncology, Vol.16, No.4, pp.525-537 
Webb A, Cunningham D, Cotter F, Clarke PA, diStefano F, Ross P, Corbo M, Dziewanowska 
Z. (1997). BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. 
Lancet, Vol.349, No.9059, pp.1137-1141 
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, 
Look AT, Aster JC. (2004). Activating mutations of NOTCH1 in human T cell acute 
lymphoblastic leukemia. Science, Vol.306, No. 5694, pp.269-271 
www.intechopen.com
Novel Aspects in Acute Lymphoblastic Leukemia
Edited by Dr. Stefan Faderl
ISBN 978-953-307-753-6
Hard cover, 258 pages
Publisher InTech
Published online 16, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Acute lymphoblastic leukemia (ALL) has turned from a universally fatal to a highly curable disease in little more
than four decades. Even though differences in outcome continue to exist between children and adults, intense
efforts are under way to overcome this discrepancy and improve the prognosis of adult patients as well. This
exemplary progress in ALL therapy has been possible by the combination of an increasingly better
understanding of the biology of the disease, availability of a range of effective drugs, and astute designs and
relentless executions of many clinical trials. ALL is a complex disease requiring complex therapy. Whereas this
book cannot provide a comprehensive review of every one of its many facets, the chapters from many
investigators from around the world nevertheless cover a number of relevant topics: aspects of the
epidemiology of ALL in Hispanics, ophthalmologic manifestations of ALL, overviews of current therapy and
drug-resistance mechanisms, novel biological pathways and targets, new drugs in development, and long-term
consequences of CNS prophylaxis and therapy. The publishers and editor therefore hope that the prospective
readers will find enough insight and information for their own endeavors.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Roman Crazzolara (2011). Novel Therapeutic Targets in ALL Therapy, Novel Aspects in Acute Lymphoblastic
Leukemia, Dr. Stefan Faderl (Ed.), ISBN: 978-953-307-753-6, InTech, Available from:
http://www.intechopen.com/books/novel-aspects-in-acute-lymphoblastic-leukemia/novel-therapeutic-targets-in-
all-therapy
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
